Understanding each critical step along with timing and potential risks requires extensive expertise. Collaborating with experienced service providers can help streamline this process while removing potential hurdles, allowing for a seamless transition from discovery into clinical development.
Charles River and Quotient Sciences can help you accelerate your path to the clinic with an integrated offering that bridges molecules from early discovery to clinical proof of concept.
Fill out the form below to receive a copy of our info sheet and schedule a time to talk with our team.
Combined, Charles River and Quotient Sciences bring to your program more than a century of experience in drug development and knowledge from our work on thousands of molecules across all stages of development.
A tight integration of activities streamlines the outsourcing model and improves decision-making, problem-solving, and technology transfer. Charles River brings deep expertise in medicinal chemistry, biology, DMPK, early pharmaceutics, and non-clinical safety, coupled with Quotient Sciences' expert knowledge of drug substance synthesis, drug product development and manufacturing, and clinical testing to create a solution under a single program of work.
Together, we provide a full set of deliverables to help get your molecule "clinic ready" and improve your chances of clinical success.
Russell Scammell, Director of Small Molecule Drug Discovery at Charles River, and Eleanor Row, Executive Director of Commercial at Quotient Sciences, talk about the recent Charles River and Quotient Sciences collaboration, and the strengths that each company brings to customer projects to bridge molecules from early discovery to proof of concept (POC) and beyond.